Article(id=1327672845737505753, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1327672822828217116, articleNumber=null, orderNo=null, doi=10.16522/j.cnki.cjph.2022.06.002, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=1650038400000, receivedDateStr=2022-04-16, revisedDate=null, revisedDateStr=null, acceptedDate=null, acceptedDateStr=null, onlineDate=1794471473391, onlineDateStr=2026-11-12, pubDate=1654790400000, pubDateStr=2022-06-10, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1794471473391, onlineIssueDateStr=2026-11-12, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1794471473391, creator=13701087609, updateTime=1794471473391, updator=13701087609, issue=Issue{id=1327672822828217116, tenantId=1146029695717560320, journalId=1319690259887390882, year='2022', volume='53', issue='6', pageStart='763', pageEnd='924', issueExtLink='null', onlineDate='null', pubDate='1654790400000', pubDateStr='2022-06-10', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1794471467930, creator='13701087609', updateTime=1794472219503, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1327675975829140467, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1327672822828217116, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1327675975829140468, tenantId=1146029695717560320, journalId=1319690259887390882, issueId=1327672822828217116, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=775, endPage=784, ext={EN=ArticleExt(id=1327672845955609562, articleId=1327672845737505753, tenantId=1146029695717560320, journalId=1319690259887390882, language=EN, title=An Update on Research Progress of Therapeutic Agents for COVID-19, columnId=1327671134809600231, journalTitle=Chinese Journal of Pharmaceuticals, columnName=Review, runingTitle=null, highlight=null, articleAbstract=
The SARS-CoV-2 infection has caused a serious public health threat globally with over 6 million deaths reported. Despite large-scale vaccination around the world, the infection rate remains high due to rapid mutations of the coronavirus, which warrants the development of novel therapeutic agents for the treatment of COVID-19. Treatment guidelines in both China and the U.S. have been updated on their recommendations regarding the recent authorizations of Paxlovid and bebtelovimab. This paper focuses on the four newly authorized agents, Paxlovid, molnupiravir, bebtelovimab, and amubarvimab/romlusevimab, for a review of their mechanisms, development progress, and clinical evidence. The characteristics and comparative use of the above agents are discussed to provide perspectives for current practice and future development.
, authors=Yue YU, Xiaoyan QIU, Mingkang ZHONG
*, authorsList=Yue YU, Xiaoyan QIU, Mingkang ZHONG, authorCompany=null, correspAuthors=Mingkang ZHONG, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1327672846668641243, articleId=1327672845737505753, tenantId=1146029695717560320, journalId=1319690259887390882, language=CN, title=新型冠状病毒肺炎治疗药物的最新研发进展, columnId=1327671135019315436, journalTitle=中国医药工业杂志, columnName=综述, runingTitle=null, highlight=null, articleAbstract=
2019新型冠状病毒(SARS-CoV-2)感染已造成全球性严重疫情,目前有超600万人死亡。尽管世界各国已经开展大范围疫苗接种,但随着病毒不断变异进化,SARS-CoV-2感染率依旧居高不下,其治疗药物的研发迫在眉睫。近期Paxlovid及bebtelovimab两款新药成功获批上市,中美两国的新型冠状病毒肺炎诊疗指南也相应更新了治疗推荐。该文聚焦于两国新型冠状病毒肺炎诊疗指南的药物推荐,将目光锁定在近期获批的4款药物Paxlovid、莫那匹韦、bebtelovimab和安巴韦单抗/罗米司韦单抗注射液,梳理总结其作用机制、研发进程及临床疗效的最新研究,并综合其作用特点及临床使用进行阐述和讨论,为未来抗新型冠状病毒药物的临床使用和进一步研发提供思路。
, authors=余悦, 邱晓燕, 钟明康
*, authorsList=余悦, 邱晓燕, 钟明康, authorCompany=null, correspAuthors=钟明康, authorNote=
余悦(1994—),女,临床药师,博士,从事临床药学和药物警戒研究。
, correspAuthorsNote=
, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=GOBLOV4f2IIWWu5RO9kJBw==, magXml=E3qD3E8QmpZTCOKq0KVj4w==, pdfUrl=null, pdf=6Rv+SU6PQpVIgtax+lOFGg==, pdfFileSize=2671795, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=+kiS/G9Jy79WEcckGS0Mfg==, mapNumber=null, fund=null)}, authors=[Author(id=1327672847096460256, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1327672847222289378, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, authorId=1327672847096460256, language=EN, stringName=Yue YU, firstName=Yue, middleName=null, lastName=YU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Dept. of Pharmacy, Huashan Hospital, Fudan University, Shanghai 200040, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1327672847301981155, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, authorId=1327672847096460256, language=CN, stringName=余悦, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=复旦大学附属华山医院药剂科,上海 200040, bio={"content":"
余悦(1994—),女,临床药师,博士,从事临床药学和药物警戒研究。
"}, bioImg=null, bioContent=
余悦(1994—),女,临床药师,博士,从事临床药学和药物警戒研究。
, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1327672847012574172, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, xref=null, ext=[AuthorCompanyExt(id=1327672847020962781, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, companyId=1327672847012574172, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Dept. of Pharmacy, Huashan Hospital, Fudan University, Shanghai 200040), AuthorCompanyExt(id=1327672847025157086, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, companyId=1327672847012574172, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=复旦大学附属华山医院药剂科,上海 200040)])]), Author(id=1327672847369090021, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1327672847436198887, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, authorId=1327672847369090021, language=EN, stringName=Xiaoyan QIU, firstName=Xiaoyan, middleName=null, lastName=QIU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Dept. of Pharmacy, Huashan Hospital, Fudan University, Shanghai 200040, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1327672847511696360, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, authorId=1327672847369090021, language=CN, stringName=邱晓燕, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=复旦大学附属华山医院药剂科,上海 200040, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1327672847012574172, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, xref=null, ext=[AuthorCompanyExt(id=1327672847020962781, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, companyId=1327672847012574172, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Dept. of Pharmacy, Huashan Hospital, Fudan University, Shanghai 200040), AuthorCompanyExt(id=1327672847025157086, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, companyId=1327672847012574172, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=复旦大学附属华山医院药剂科,上海 200040)])]), Author(id=1327672847566222314, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=mkzhong_hs@126.com, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1327672847641719788, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, authorId=1327672847566222314, language=EN, stringName=Mingkang ZHONG, firstName=Mingkang, middleName=null, lastName=ZHONG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
*, address=Dept. of Pharmacy, Huashan Hospital, Fudan University, Shanghai 200040, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1327672847721411565, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, authorId=1327672847566222314, language=CN, stringName=钟明康, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=
*, address=复旦大学附属华山医院药剂科,上海 200040, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1327672847012574172, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, xref=null, ext=[AuthorCompanyExt(id=1327672847020962781, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, companyId=1327672847012574172, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Dept. of Pharmacy, Huashan Hospital, Fudan University, Shanghai 200040), AuthorCompanyExt(id=1327672847025157086, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, companyId=1327672847012574172, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=复旦大学附属华山医院药剂科,上海 200040)])])], keywords=[Keyword(id=1327672847813686254, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, language=EN, orderNo=1, keyword=SARS-CoV-2), Keyword(id=1327672847876600815, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, language=EN, orderNo=2, keyword=COVID-19), Keyword(id=1327672847926932464, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, language=EN, orderNo=3, keyword=therapeutic drug), Keyword(id=1327672847998235633, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, language=EN, orderNo=4, keyword=emergency use authorization), Keyword(id=1327672848065344498, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, language=EN, orderNo=5, keyword=research progress), Keyword(id=1327672848124064755, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, language=EN, orderNo=6, keyword=clinical use), Keyword(id=1327672848182785012, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, language=CN, orderNo=1, keyword=2019新型冠状病毒), Keyword(id=1327672848245699573, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, language=CN, orderNo=2, keyword=新型冠状病毒肺炎), Keyword(id=1327672848308614134, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, language=CN, orderNo=3, keyword=治疗药物), Keyword(id=1327672848371528695, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, language=CN, orderNo=4, keyword=紧急使用授权), Keyword(id=1327672848434443256, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, language=CN, orderNo=5, keyword=研发进展), Keyword(id=1327672848488969209, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, language=CN, orderNo=6, keyword=临床使用)], refs=[Reference(id=1327672848593826810, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=KANNAN S, SHAIK S A P, SHEEZA A.Omicron(B.1.1.529) - variant of concern - molecular profile and epidemiology: a mini review [J].
Eur Rev Med Pharmacol Sci, 2021,
25(24): 8019-8022., articleTitle=null, refAbstract=null), Reference(id=1327672848656741371, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=WHO.WHO coronavirus(COVID-19) dashboard [EB/OL].(2022-04-09)[2022-04-09].
https://covid19.who.int/., articleTitle=null, refAbstract=null), Reference(id=1327672848774181884, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=WHO.WHO living guideline: therapeutics and COVID-19[EB/OL].(2022-03-03)[2022-03-30].
https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2022.2., articleTitle=null, refAbstract=null), Reference(id=1327672848845485053, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=MURALIDAR S, AMBI S V, SEKARAN S,
et al.The emergence of COVID-19 as a global pandemic: understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2 [J].
Biochimie,2020,
179: 85-100., articleTitle=null, refAbstract=null), Reference(id=1327672848920982526, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=李沛霖,刘海英.SARS-CoV-2入侵细胞相关分子结构与机制的研究进展[J].生命科学,2021,
33(3):337-345., articleTitle=null, refAbstract=null), Reference(id=1327672849030034431, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=张林丽,刘莉.新型冠状病毒肺炎药物进展[J].海峡药学,2021,
33(1):119-122., articleTitle=null, refAbstract=null), Reference(id=1327672849101337600, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=戚文涛,鞠翰,侯凌欣,等.新型冠状病毒检测以及相关药物研发中的基础药学知识[J].大学化学,2020,
35(12):21-28., articleTitle=null, refAbstract=null), Reference(id=1327672849176834048, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Fact sheet for healthcare providers: emergency use authorization for Paxlovid
TM [EB/OL].(2022-03-18)[2022-04-02].
https://www.fda.gov/media/155050/download., articleTitle=null, refAbstract=null), Reference(id=1327672849243942913, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=国家药品监督管理局.国家药监局应急附条件批准辉瑞公司新冠病毒治疗药物奈玛特韦片/利托那韦片组合包装进口注册[EB/OL].(2022-02-12)[2022-04-02].
https://www.nmpa.gov.cn/zhuanti/yqyjzxd/yqyjxd/20220212085753142.html., articleTitle=null, refAbstract=null), Reference(id=1327672849311051778, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=RAMOS-GUZMÁN C A, RUIZ-PERNÍA J J, TUÑÓN I.Computational simulations on the binding and reactivity of a nitrile inhibitor of the SARS-CoV-2 main protease [J].
Chem Commun, 2021,
57(72): 9096-9099., articleTitle=null, refAbstract=null), Reference(id=1327672849382354947, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=AHMAD B, BATOOL M, AIN Q U,
et al.Exploring the binding mechanism of PF-07321332 SARS-CoV-2 protease inhibitor through molecular dynamics and binding free energy simulations [J].
Int J Mol Sci, 2021,
22(17):9124., articleTitle=null, refAbstract=null), Reference(id=1327672849449463812, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=陈本川.治疗新型冠病毒肺炎新药—奈玛特韦(nirmatrelvir)片与利托那韦片组合用药Paxlovid
@[J].医药导报, 2022-03-17(知网网络首发)., articleTitle=null, refAbstract=null), Reference(id=1327672849516572677, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=HULL M W, MONTANER J S G.Ritonavir-boosted protease inhibitors in HIV therapy [J].
Ann Med, 2011,
43(5): 375-388., articleTitle=null, refAbstract=null), Reference(id=1327672849596264454, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[14], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=OWEN D R, ALLERTON C M N, ANDERSON A S,
et al.An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19 [J].
Science, 2021,
374(6575):1586-1593., articleTitle=null, refAbstract=null), Reference(id=1327672849675956231, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=CHIA C S B.Novel nitrile peptidomimetics for treating COVID-19 [J].
ACS Med Chem Lett, 2022,
13(3): 330-331., articleTitle=null, refAbstract=null), Reference(id=1327672849751453704, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=Pfizer.Pfizer initiates phase 2/3 study of novel COVID-19 oral treatment in pediatric participants [EB/OL].(2022-03-09)[2022-04-05].
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-initiates-phase-23-study-novel-covid-19-oral., articleTitle=null, refAbstract=null), Reference(id=1327672849822756873, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=HAMMOND J, LEISTER-TEBBE H, GARDNER A,
et al.Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19 [J].
N Engl J Med, 2022,
386: 1397-1408., articleTitle=null, refAbstract=null), Reference(id=1327672849894060042, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=Pfizer.Pfizer announces additional phase 2/3 study results confirming robust efficacy of novel COVID-19 oral antiviral treatment candidate in reducing risk of hospitalization or death [EB/OL].(2021-12-14)[2022-04-05].
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-additional-phase-23-study-results., articleTitle=null, refAbstract=null), Reference(id=1327672849961168907, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=Pfizer.Pfizer shares
in vitro efficacy of novel COVID-19 oral treatment against Omicron variant [EB/OL].(2022-01-18)[2022-04-05].
https://www.pfizer.com/news/press-release/press-release-detail/pfizer-shares-vitro-efficacy-novel-covid-19-oral-treatment., articleTitle=null, refAbstract=null), Reference(id=1327672850019889164, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Fact sheet for healthcare providers: emergency use authorization for LAGEVRIO
TM(molnupiravir) capsules[EB/OL].(2022-03-30)[2022-04-08].
https://www.fda.gov/media/155054/download., articleTitle=null, refAbstract=null), Reference(id=1327672850082803725, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=GOSTINI M L, PRUIJSSERS A J, CHAPPELL J D,
et al.Small-molecule antiviral β-D-
N4-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance [J].
J Virol, 2019,
93(24): e0134-19., articleTitle=null, refAbstract=null), Reference(id=1327672850166689806, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=GORDON C J, TCHESNOKOV E P, SCHINAZI R F,
et al.Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template [J].
J Biol Chem, 2021,
297(1): 100770., articleTitle=null, refAbstract=null), Reference(id=1327672850233798671, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=KABINGER F, STILLER C, SCHMITZOVÁ J,
et al.Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis [J].
Nat Struct Mol Biol, 2021,
28(9): 740-746., articleTitle=null, refAbstract=null), Reference(id=1327672850296713232, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=PAINTER W P, HOLMAN W, BUSH J A,
et al.Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2 [J].
Antimicrob Agents Chemother,2021,
65(5): e02428-20., articleTitle=null, refAbstract=null), Reference(id=1327672850363822097, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=PAINTER G R, NATCHUS M G, COHEN O,
et al.Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19 [J].
Curr Opin Virol, 2021,
50:17-22., articleTitle=null, refAbstract=null), Reference(id=1327672850439319570, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=FIER P S, XU Y, POIRIER M,
et al.Development of a robust manufacturing route for molnupiravir, an antiviral for the treatment of COVID-19 [J].
Org Process Res Dev,2021,
25(12): 2806-2815., articleTitle=null, refAbstract=null), Reference(id=1327672850506428435, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=IMRAN M, KUMAR ARORA M, ASDAQ S M B,
et al.Discovery, development, and patent trends on molnupiravir: a prospective oral treatment for COVID-19 [J].
Molecules,2021,
26(19): 5795., articleTitle=null, refAbstract=null), Reference(id=1327672850594508820, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=STEINER A, ZNIDAR D, ÖTVÖS S B,
et al.A high-yielding synthesis of EIDD-2801 from uridine [J].
Eur J Org Chem, 2020,
2020(43): 6736-6739., articleTitle=null, refAbstract=null), Reference(id=1327672850674200597, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=Merck.Merck and Ridgeback's molnupiravir, an oral COVID-19 antiviral medicine, receives first authorization in the world [EB/OL].(2021-11-04)[2022-04-09].
https://www.merck.com/news/merck-and-ridgebacks-molnupiravir-an-oral-covid-19-antiviral-medicine-receives-first-authorization-in-the-world/., articleTitle=null, refAbstract=null), Reference(id=1327672850766475286, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=JAYK BERNAL A, GOMES DA SILVA M M, MUSUNGAIE D B,
et al.Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients [J].
N Engl J Med, 2022,
386(6):509-520., articleTitle=null, refAbstract=null), Reference(id=1327672850833584151, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=Merck.Merck and Ridgeback to present data demonstrating that treatment with LAGEVRIO
TM(molnupiravir) was associated with more rapid elimination of infectious SARS-CoV-2 than placebo [EB/OL].(2022-04-01)[2022-04-09].
https://www.merck.com/news/merck-and-ridgeback-to-present-data-demonstrating-that-treatment-with-lagevrio-molnupiravir-was-associated-with-more-rapid-elimination-of-infectious-sars-cov-2-than-placebo/., articleTitle=null, refAbstract=null), Reference(id=1327672850955218968, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=LI P, WANG Y, LAVRIJSEN M,
et al.SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination [J].
Cell Res, 2022,
32(3): 322-324., articleTitle=null, refAbstract=null), Reference(id=1327672851026522137, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Fact sheet for healthcare providers: emergency use authorization for bebtelovimab [EB/OL].(2022-03-30)[2022-04-02].
https://www.fda.gov/media/156152/download., articleTitle=null, refAbstract=null), Reference(id=1327672851089436698, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=AbCellera.AbCellera-discovered antibody, bebtelovimab, receives U.S. FDA emergency use authorization for the treatment of mild-to-moderate COVID-19 [EB/OL].(2022-02-11)[2022-04-03].
https://www.abcellera.com/news/bebtelovimab-receives-eua., articleTitle=null, refAbstract=null), Reference(id=1327672851156545563, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=JONES B E, BROWN-AUGSBURGER P L, CORBETT K S,
et al.The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates [J].
Sci Transl Med, 2021,
13(593): eabf1906., articleTitle=null, refAbstract=null), Reference(id=1327672851215265820, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=WESTENDORF K, ŽENTELIS S, WANG L,
et al.LY-CoV1404(bebtelovimab) potently neutralizes SARS-CoV-2 variants [J].
Cell Rep, 2022,
39(7): 110812., articleTitle=null, refAbstract=null), Reference(id=1327672851278180381, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=IKETANI S, LIU L, GUO Y,
et al.Antibody evasion properties of SARS-CoV-2 Omicron sublineages [J].
Nature, 2022,
604(7906): 553-556., articleTitle=null, refAbstract=null), Reference(id=1327672851336900638, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=国家卫生健康委员会,国家中医药管理局.新型冠状病毒肺炎诊疗方案(试行第九版)[EB/OL].(2022-03-14)[2022-04-02].
http://www.gov.cn/zhengce/zhengceku/2022-03/15/5679257/files/49854a49c7004f4ea9e622f3f2c568d8.pdf., articleTitle=null, refAbstract=null), Reference(id=1327672851424981023, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=GE J, WANG R, JU B,
et al.Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry [J].
Nat Commun, 2021,
12(1): 250., articleTitle=null, refAbstract=null), Reference(id=1327672851492089888, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=单思思,王若珂,张绮,等.安巴韦单抗注射液(BRⅡ-196)及罗米司韦单抗注射液(BRⅡ-198)——中国首个自主知识产权新冠病毒中和抗体联合治疗药物[J].中国医药导刊,2022,
24(1):2-8., articleTitle=null, refAbstract=null), Reference(id=1327672851559198753, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=SHRESTHA L B, TEDLA N, BULL R A.Broadly-neutralizing antibodies against emerging SARS-COV-2 variants [J].
Front Immunol, 2021,
12: 752003., articleTitle=null, refAbstract=null), Reference(id=1327672851622113314, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=WANG R, ZHANG Q, GE J,
et al.Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species[J].
Immunity, 2021,
54(7): 1611-1621., articleTitle=null, refAbstract=null), Reference(id=1327672851685027875, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[43], rfOrder=42, authorNames=null, journalName=null, refType=null, unstructuredReference=JU B, ZHANG Q, GE J,
et al.Human neutralizing antibodies elicited by SARS-CoV-2 infection [J].
Nature,2020,
584(7819): 115-119., articleTitle=null, refAbstract=null), Reference(id=1327672851743748132, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[44], rfOrder=43, authorNames=null, journalName=null, refType=null, unstructuredReference=SELF W H, SANDKOVSKY U, REILLY C S,
et al.Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRⅡ-196 plus BRⅡ-198, for adults hospitalised with COVID-19(TICO): a randomised controlled trial [J].
Lancet Infect Dis, 2021,
S1473-3099(21): 751-759., articleTitle=null, refAbstract=null), Reference(id=1327672851819245605, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[45], rfOrder=44, authorNames=null, journalName=null, refType=null, unstructuredReference=LIU L, IKETANI S, GUO Y,
et al.Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 [J].
Nature, 2022,
602(7898): 676-681., articleTitle=null, refAbstract=null), Reference(id=1327672851890548774, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[46], rfOrder=45, authorNames=null, journalName=null, refType=null, unstructuredReference=LUSVARGHI S, POLLETT S D, NEERUKONDA S N,
et al.SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum, but evades most convalescent serum and therapeutic antibodies [J].
Sci Transl Med, 2022,
14(645): eabn8543., articleTitle=null, refAbstract=null), Reference(id=1327672851957657639, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[47], rfOrder=46, authorNames=null, journalName=null, refType=null, unstructuredReference=NIH.Coronavirus disease 2019(COVID-19) treatment guidelines [EB/OL].(2022-04-08)[2022-04-09].
https://www.covid19treatmentguidelines.nih.gov/., articleTitle=null, refAbstract=null), Reference(id=1327672852054126632, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[48], rfOrder=47, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.Coronavirus(COVID-19) update: FDA authorizes new monoclonal antibody for treatment of COVID-19 that retains activity against Omicron variant [EB/OL].(2022-02-11)[2022-04-09].
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-new-monoclonal-antibody-treatment-covid-19-retains., articleTitle=null, refAbstract=null), Reference(id=1327672852129624105, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[49], rfOrder=48, authorNames=null, journalName=null, refType=null, unstructuredReference=FDA.FDA updates sotrovimab emergency use authorization[EB/OL].(2022-04-05)[2022-04-09].
https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-sotrovimab-emergency-use-authorization?msclkid=40021cb7af1411ec86413f9a1bc7c7a2., articleTitle=null, refAbstract=null), Reference(id=1327672852242870314, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[50], rfOrder=49, authorNames=null, journalName=null, refType=null, unstructuredReference=冯昭.让新冠终结在春光里——揭秘首款国产抗新冠特效药诞生的故事[J].中国品牌, 2022, (1): 54-61., articleTitle=null, refAbstract=null), Reference(id=1327672852335145003, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[51], rfOrder=50, authorNames=null, journalName=null, refType=null, unstructuredReference=NBC.XE variant: what to know about the new hybrid strain first identified in UK [EB/OL].(2022-04-04)[2022-04-06].
https://www.nbcchicago.com/news/local/xe-variant-what-to-know-about-the-new-hybrid-strain-first-identified-in-uk/2798743/?msclkid=b56a15e5b5b411ecb526d1760ba937a3., articleTitle=null, refAbstract=null)], funds=null, companyList=[AuthorCompany(id=1327672847012574172, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, xref=null, ext=[AuthorCompanyExt(id=1327672847020962781, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, companyId=1327672847012574172, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Dept. of Pharmacy, Huashan Hospital, Fudan University, Shanghai 200040), AuthorCompanyExt(id=1327672847025157086, tenantId=1146029695717560320, journalId=1319690259887390882, articleId=1327672845737505753, companyId=1327672847012574172, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=复旦大学附属华山医院药剂科,上海 200040)])], figs=null, attaches=null, journal=Journal(id=1319689822849302687, delFlag=0, nameCn=中国医药工业杂志, nameEn=Chinese Journal of Pharmaceuticals, nameHistory1=null, nameHistory2=null, issn=1001-8255, eissn=null, cn=31-1243/R, coden=ZYGZEA, periodic=0, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=etiWDuwx2KO274LHw88KJA==, journalPrice=null, startedYear=null, abbrevIsoEn=Chinese Journal of Pharmaceuticals, journalRemark=null, publicationField=null, createdTime=1792568172420, updatedTime=1792747450744, createdBy=18614031015, updatedBy=13701087609, firstLetterCn=Z, firstLetterEn=Z, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=etiWDuwx2KO274LHw88KJA==, picEn=ip9NF4dK57AmNrCiZ6hmdw==, jcr=null, cjcr=null, exts=[JournalExt(id=1320441770761105589, language=CN, name=中国医药工业杂志, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747450771, updatedTime=1792747450771, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://zgyygyauthor.cast.org.cn/webm, submissionEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionReviewUrl=https://zgyygyauthor.cast.org.cn/webm, submissionCeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionAeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, option={"copyright":""}), JournalExt(id=1320441770819825846, language=EN, name=Chinese Journal of Pharmaceuticals, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1792747450785, updatedTime=1792747450785, createdBy=13701087609, updatedBy=13701087609, submissionGuidelinesUrl=, submissionAuthorUrl=https://zgyygyauthor.cast.org.cn/webm, submissionEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionReviewUrl=https://zgyygyauthor.cast.org.cn/webm, submissionCeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, submissionAeEditorUrl=https://zgyygyeditor.cast.org.cn/webm, option={"copyright":""})], databaseList=null, tenantJournalId=1319690259887390882, websiteList=[Website(id=1319720771623174732, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690259887390882, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgyygy/CN, language=CN, createTime=1792575551181, createBy=18614031015, updateTime=1792746040843, updateBy=18614031015, name=中国医药工业杂志-中文, tplId=1146099689490845704, title=中国医药工业杂志, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428487504769041, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=articleTextType, value=kx, createTime=1792982702375, updateTime=1792982702375, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487475408910, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=banner, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic?fileId=i/3+mr8MqWvs6ArWn9VK7w==, createTime=1792982702368, updateTime=1792982702368, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487538323476, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=grayFlag, value=0, createTime=1792982702383, updateTime=1792982702383, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487462825997, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=logo, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic?fileId=7mfvc3zMp/tsQUIOlJrNFQ==, createTime=1792982702365, updateTime=1792982702365, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487571877910, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=minRunFlag, value=0, createTime=1792982702391, updateTime=1792982702391, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487496380432, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgyygy/CN/file/pic, createTime=1792982702373, updateTime=1792982702373, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487563489301, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=silenceFlag, value=0, createTime=1792982702389, updateTime=1792982702389, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487483797519, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1792982702370, updateTime=1792982702370, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487517351954, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=themeColor, value=null, createTime=1792982702378, updateTime=1792982702378, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428487525740563, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771623174732, code=themeStyle, value=.style-1 .main-menu ul>li {
margin-right: 18px;
}
@media (max-width: 1442px) {
.style-1 .main-menu ul>li a {
font-size: 16px;
padding: 10px 0;
}
}, createTime=1792982702380, updateTime=1792982702380, creator=18614031015, updator=18614031015)]), Website(id=1319720771702866512, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1319690259887390882, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgyygy/EN, language=EN, createTime=1792575551200, createBy=18614031015, updateTime=1792746037543, updateBy=18614031015, name=中国医药工业杂志-英文, tplId=1146101810881728533, title=Chinese Journal of Pharmaceuticals, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1321428509638111261, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=articleTextType, value=kx, createTime=1792982707652, updateTime=1792982707652, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509579391002, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=banner, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic?fileId=i/3+mr8MqWvs6ArWn9VK7w==, createTime=1792982707638, updateTime=1792982707638, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509680054304, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=grayFlag, value=0, createTime=1792982707662, updateTime=1792982707662, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509566808089, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=logo, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic?fileId=7mfvc3zMp/tsQUIOlJrNFQ==, createTime=1792982707635, updateTime=1792982707635, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509701025826, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=minRunFlag, value=0, createTime=1792982707667, updateTime=1792982707667, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509629722652, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgyygy/EN/file/pic, createTime=1792982707650, updateTime=1792982707650, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509688442913, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=silenceFlag, value=0, createTime=1792982707664, updateTime=1792982707664, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509587779611, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1792982707640, updateTime=1792982707640, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509663277086, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=themeColor, value=null, createTime=1792982707658, updateTime=1792982707658, creator=18614031015, updator=18614031015), WebsiteProps(id=1321428509671665695, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1319720771702866512, code=themeStyle, value=.style-1 .main-menu ul>li {
margin-right: 18px;
}
@media (max-width: 1442px) {
.style-1 .main-menu ul>li a {
font-size: 16px;
padding: 10px 0;
}
}, createTime=1792982707660, updateTime=1792982707660, creator=18614031015, updator=18614031015)])], journalTitle=中国医药工业杂志, weixinUrl=null, journalUrl=http://www.cjph.com.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=Chinese Journal of Pharmaceuticals, journalPhotoCn=etiWDuwx2KO274LHw88KJA==, journalPhotoEn=ip9NF4dK57AmNrCiZ6hmdw==, journalFirstLetter=Z, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/zgyygy/CN/10.16522/j.cnki.cjph.2022.06.002, detailUrlEn=https://castjournals.cast.org.cn/joweb/zgyygy/EN/10.16522/j.cnki.cjph.2022.06.002, pdfUrlCn=https://castjournals.cast.org.cn/joweb/zgyygy/CN/PDF/10.16522/j.cnki.cjph.2022.06.002, pdfUrlEn=https://castjournals.cast.org.cn/joweb/zgyygy/EN/PDF/10.16522/j.cnki.cjph.2022.06.002, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1654790400000, fullTextJson=null, articleText=null, reference=null)